07:06 AM EDT, 10/08/2026 (MT Newswires) -- BofA Global Research sees scope for Roche (RO.SW) to potentially raise its full-year 2026 EPS outlook, even as the Swiss drugmaker is expected to report "in-line" third-quarter sales on Oct. 22. "We see possible upgrade to current high-sd % EPS guide on potential margin expansion or better tax rate achieved in 2H, although Roche doesn't report P&L at 3Q. That said, we do not yet factor a guide upgrade into our current estimates. We see less scope for sales upgrade due to continued base business pressures," analysts said Thursday. "We flag Fx now c1% better than 2Q guide based on end-Sep rates, now -4% Group sales and -5% EBIT/EPS." The research firm forecasts third-quarter group and pharmaceutical sales to rise 5% year over year to 15.6 billion francs and 12.1 billion francs, respectively, meeting market expectations. Looking ahead to 2027, BofA models 5% annual group sales growth and expects a repeat of the 2026 outlook, with a target of mid-to-high single-digit EPS gain and mid-single-digit sales at constant currencies. Against this backdrop, BofA reiterated its buy rating on the stock, supported by a "bullish view" on near-term launches, including giredestrant, divarasib and fenebrutinib, as well as a "busier" pipeline in 2027 and 2028. The research firm has a price objective of 415 francs on the stock.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.